MedTrace Logo

Effects of Anti-TSLP in Patients With Asthma

NCT02698501 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2021-06-02

No results posted yet for this study

Summary

The purpose of this study is to determine whether anti-TSLP will decrease airway hyperresponsiveness in patients with asthma already on daily treatment with inhaled corticosteroids.

The investigators expect that airway hyperresponsiveness will decrease after treatment with anti-TSLP, and that this happens due to a change in the type of mast cells with in the lungs. Also, the investigators expect a decrease in inflammatory cells and mediators measured in material from the lungs.

Half of the participants will receive anti-TSLP (MEDI9929) on top of their regular asthma treatment, while the other half will receive placebo on top of their regular asthma treatment.

Conditions

Interventions

DRUG

MEDI9929

MEDI9929 700mg (3 doses in total, 4-week intervals), administered intravenously

DRUG

Placebo

Placebo (3 doses in total, 4-week intervals), administered intravenously

Sponsors & Collaborators

  • Lund University

    collaborator OTHER

  • University of Newcastle, Australia

    collaborator OTHER

  • University of Copenhagen

    collaborator OTHER

  • Celeste Porsbjerg

    lead OTHER

Principal Investigators

  • Celeste Porsbjerg, MD, PhD · Copehagen University Hospital Bispebjerg, Copenhagen, Denmark

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-08-31
Primary Completion
2019-08-07
Completion
2019-10-07

Countries

  • Denmark

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02698501 on ClinicalTrials.gov